Comparative Effects of Metamizole (Dipyrone) and Naproxen on Renal Function and Prostacyclin Synthesis in Salt-Depleted Healthy Subjects - A Randomized Controlled Parallel Group Study
Open Access
- 7 September 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
Aim: The objective was to investigate the effect of metamizole on renal function in healthy, salt-depleted volunteers. In addition, the pharmacokinetics of the four major metamizole metabolites were assessed and correlated with the pharmacodynamic effect using urinary excretion of the prostacyclin metabolite 6-keto-prostaglandin F1α.Methods: Fifteen healthy male volunteers were studied in an open-label randomized controlled parallel group study. Eight subjects received oral metamizole 1,000 mg three times daily and seven subjects naproxen 500 mg twice daily for 7 days. All subjects were on a low sodium diet (50 mmol sodium/day) starting 1 week prior to dosing until the end of the study. Glomerular filtration rate was measured using inulin clearance. Urinary excretion of sodium, potassium, creatinine, 6-keto-prostaglandin F1α, and pharmacokinetic parameters of naproxen and metamizole metabolites were assessed after the first and after repeated dosing.Results: In moderately sodium-depleted healthy subjects, single or multiple dose metamizole or naproxen did not significantly affect inulin and creatinine clearance or sodium excretion. Both drugs reduced renal 6-keto-prostaglandin F1α excretion after single and repeated dosing. The effect started 2 h after intake, persisted for the entire dosing period and correlated with the concentration-profile of naproxen and the active metamizole metabolite 4-methylaminoantipyrine (4-MAA). PKPD modelling indicated less potent COX-inhibition by 4-MAA (EC50 0.69 ± 0.27 µM) compared with naproxen (EC50 0.034 ± 0.033 µM).Conclusions: Short term treatment with metamizole or naproxen has no significant effect on renal function in moderately sodium depleted healthy subjects. At clinically relevant doses, 4-MAA and naproxen both inhibit COX-mediated renal prostacyclin synthesis.Keywords
This publication has 60 references indexed in Scilit:
- Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trialsThe Lancet, 2013
- A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoidsJournal of Lipid Research, 2012
- Novel bioactive metabolites of dipyrone (metamizol)Bioorganic & Medicinal Chemistry, 2012
- Quantification of urinary PGEm, 6-keto PGF1α and 2,3-dinor-6-keto PGF1α by UFLC–MS/MS before and after exerciseProstaglandins & Other Lipid Mediators, 2010
- Nonsteroidal Anti-Inflammatory Drugs and the KidneyPharmaceuticals, 2010
- Inhibition of Cyclooxygenases by DipyroneBritish Journal of Pharmacology, 2007
- Drug-Induced AnaphylaxisDrug Safety, 2005
- Level of hydration and renal function in healthy humansKidney International, 2001
- Clinical Pharmacokinetics of Dipyrone and its MetabolitesClinical Pharmacokinetics, 1995
- Fully Enzymatic Inulin Determination in Small Volume Samples without DeproteinizationNephron, 1992